AQUESTIVE THERAPEUTICS INC (AQST) — insider trading
Health Care · NASDAQ
AQUESTIVE THERAPEUTICS INC (AQST) has 42 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 42 (latest 2026-10-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Barber Daniel | Director, Officer (President and CEO) | Open-market sale | 25,000 | $4.22 | $105.6K | Form 4 |
| 2026-09-15 | Barber Daniel | Director, Officer (President and CEO) | Open-market sale | 25,000 | $4.82 | $120.5K | Form 4 |
| 2026-09-09 | Korczynski Sherry | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 8,750 | — | $0 | Form 4 |
| 2026-09-09 | Korczynski Sherry | Officer (Chief Commercial Officer) | Open-market sale | 8,750 | $5.22 | $45.7K | Form 4 |
| 2026-09-09 | Korczynski Sherry | Officer (Chief Commercial Officer) | Option exercise / conversion | 8,750 | $2.65 | $23.2K | Form 4 |
| 2026-09-09 | Boyd Peter E. | Officer (Chief People Officer) | Option exercise (in/at-the-money) (derivative) | 2,293 | — | $0 | Form 4 |
| 2026-09-09 | Boyd Peter E. | Officer (Chief People Officer) | Option exercise (in/at-the-money) | 2,293 | $0.96 | $2.2K | Form 4 |
| 2026-09-08 | Barber Daniel | Director, Officer (President and CEO) | Option exercise (in/at-the-money) (derivative) | 91,743 | — | $0 | Form 4 |
| 2026-09-08 | Barber Daniel | Director, Officer (President and CEO) | Option exercise (in/at-the-money) | 91,743 | $0.96 | $88.1K | Form 4 |
| 2026-09-03 | Jung Cassie | Officer (Chief Operating Officer) | Option exercise (in/at-the-money) (derivative) | 4,587 | — | $0 | Form 4 |
| 2026-09-03 | Jung Cassie | Officer (Chief Operating Officer) | Option exercise (in/at-the-money) | 4,587 | $0.96 | $4.4K | Form 4 |
| 2026-08-17 | Barber Daniel | Director, Officer (President and CEO) | Open-market sale | 25,000 | $4.29 | $107.2K | Form 4 |
| 2026-08-14 | Korczynski Sherry | Officer (Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 2,714 | $4.25 | $11.5K | Form 4 |
| 2026-07-16 | Barber Daniel | Officer (President and CEO) | Open-market sale | 20,369 | $4.00 | $81.5K | Form 4 |
| 2026-07-15 | Barber Daniel | Officer (President and CEO) | Open-market sale | 4,631 | $4.03 | $18.7K | Form 4 |
| 2026-06-23 | Krop Julie | Director | Option exercise / conversion (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-06-23 | Krop Julie | Director | Open-market sale | 25,000 | $5.02 | $125.4K | Form 4 |
| 2026-06-23 | Krop Julie | Director | Option exercise / conversion | 25,000 | $0.7132 | $17.8K | Form 4 |
| 2026-06-15 | Barber Daniel | Officer (President and CEO) | Open-market sale | 25,000 | $4.16 | $104.0K | Form 4 |
| 2026-06-10 | Taglietti Marco | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-10 | BROWN GREGORY B | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-10 | Cochran John | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-10 | Jenkins Abigail L. | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-10 | Krop Julie | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-10 | MORRIS TIMOTHY E | Director | Grant / award / vesting (derivative) | 50,500 | — | $0 | Form 4 |
| 2026-06-08 | Korczynski Sherry | Officer (Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 2,714 | — | $0 | Form 4 |
| 2026-05-18 | Zalewski Thomas A. | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 75,000 | — | $0 | Form 4 |
| 2026-05-18 | Zalewski Thomas A. | Officer (Chief Legal Officer) | Grant / award / vesting | 100,000 | — | $0 | Form 4 |
| 2026-05-15 | Cioffi Melina | Officer (SVP, Regulatory Affairs) | Shares withheld for taxes / exercise cost | 1,667 | $4.17 | $7.0K | Form 4 |
| 2026-05-15 | Barber Daniel | Officer (President and CEO) | Open-market sale | 8,257 | $4.29 | $35.4K | Form 4 |
| 2026-05-07 | BRAENDER LORI J | Officer (Corporate Secretary) | Shares withheld for taxes / exercise cost | 135,690 | $4.23 | $574.0K | Form 4 |
| 2026-05-05 | BRAENDER LORI J | Officer (Corporate Secretary) | Shares withheld for taxes / exercise cost | 76,147 | $4.18 | $318.3K | Form 4 |
| 2026-05-05 | Jung Cassie | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 72,734 | $4.18 | $304.0K | Form 4 |
| 2026-05-05 | TOTH A ERNEST JR | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 92,652 | $4.18 | $387.3K | Form 4 |
| 2026-05-05 | Barber Daniel | Officer (President and CEO) | Shares withheld for taxes / exercise cost | 335,922 | $4.18 | $1.40M | Form 4 |
| 2026-05-05 | Boyd Peter E. | Officer (Chief People Officer) | Shares withheld for taxes / exercise cost | 56,778 | $4.18 | $237.3K | Form 4 |
| 2025-03-07 | BRAENDER LORI J | Officer (Corporate Secretary) | Grant / award / vesting (derivative) | 82,500 | — | $0 | Form 4 |
| 2025-03-07 | Korczynski Sherry | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 67,500 | — | $0 | Form 4 |
| 2025-03-07 | TOTH A ERNEST JR | Officer (SVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 82,500 | — | $0 | Form 4 |
| 2025-03-07 | Jung Cassie | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2025-03-07 | Boyd Peter E. | Officer (Chief People Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2025-03-07 | Barber Daniel | Officer (President and CEO) | Grant / award / vesting (derivative) | 293,100 | — | $0 | Form 4 |
Ask the chat about AQST's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AQUESTIVE THERAPEUTICS INC (AQST).
Last updated 2026-10-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.